Loss of Heterozygosity
Genomic Loss of Heterozygosity or genomic instability is often related to defective homologous recombination repair mechanisms.
Loss of Heterozygosity (LOH)
Caris utilizes MI Exome™ (whole exome sequencing) to analyze 250,000 evenly-spaced single nucleotide polymorphisms (SNP) to measure genomic instability in the tumor. Genomic Loss of Heterozygosity (LOH) or genomic instability is often related to defective homologous recombination repair mechanisms. High levels of genomic instability may be indicative of PARP inhibitor and platinum therapy response.
Genomic Signatures
| Biomarker | Method | Analyze | Result |
|---|---|---|---|
| Genomic Loss of Heterozygosity (LOH) | Seq | DNA-Tumor | High-38% of tested genomic segments exhibited LOH (assay threshold is ≥ 16%) |
Genomic LOH testing is provided at no additional cost and no increase in specimen requirements or turnaround time when Caris molecular profiling is ordered. The results can be found in the Genomic Signatures section of the Caris molecular profiling report, alongside Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB) results.
What is Loss of Heterozygosity (LOH)?
- Normally, there are 2 copies of every gene in a person’s DNA (excluding sex chromosomes in males)
- When the copies are not identical, the person is considered heterozygous at that gene location
- In cancer, DNA damage events can occur in the cell that causes the loss of one copy
- In the second example shown here, the cell has lost copy B and, therefore, is no longer heterozygous at this location.
- LOH can occur at the single-gene level or genome wide – which is called Genomic LOH
- Single-gene level: In a person heterozygous for a tumor suppressor gene (one functional copy and one disabled copy), the loss of the functional copy can lead to cancer, as the person no longer has a working version of the tumor suppressor.
- Genome-wide: When a person has lost a critical gene involved in DNA repair, chromosome deletions can appear throughout the genome, resulting in LOH at thousands of locations. Even if the DNA repair gene alteration is missed in testing, the detection of genomic LOH can identify a tumor that may be susceptible to drugs that impact the DNA-damage/repair pathway (PARP inhibitors or platinum agents).
- The Caris assay measures genomic LOH in order to identify cases of potential homologous recombination deficiency that are not identified with standard NGS.
Homologous Chromosomes
The cell has lost copy B and, therefore, is no longer heterozygous at this location.
Caris Molecular Profiling Menu by Region
International & US
Review and download the Caris molecular profiling testing menu for US and International cases.
Download
New York
Review and download the Caris molecular profiling testing menu for New York state cases.
Download
European Union (EU)
Review and download the Caris molecular profiling testing menu for European cases.
DownloadCaris Molecular Profiling Menu by Region
International & US
Review and download the Caris molecular profiling testing menu for US and International cases.
New York
Review and download the Caris molecular profiling testing menu for New York state cases.
European Union (EU)
Review and download the Caris molecular profiling testing menu for European cases.
Please complete the form below to have a Caris Scientific Rep (Medical Science Liaison) contact you directly.
"*" indicates required fields
Order Profiling
Place an order today for a comprehensive, personalized Caris profiling report.